Improvement of right ventricular function in pulmonary arterial hypertension with disease-specific therapy - A clinical observational study

Acta Cardiologica Sinica

Volumn 30, Issue 3, 2014, Pages 236-244

  Ho, Wan Jing ^a   Lin, Chia Pin ^a   Wang, Chun Li ^a   Hsu, Lung An ^a   Yu, Kuang Hui ^a   Luo, Shue Fen ^a   Chen, Ji Yih ^a   Hsu, Tsu Shiu ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Disease specific therapy; Pulmonary arterial hypertension; Right ventricular function

Indexed keywords

AMBRISENTAN; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; TREPROSTINIL;

ADULT; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CLINICAL ARTICLE; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEART CATHETERIZATION; HEART PERFORMANCE; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE FUNCTION; HUMAN; IDIOPATHIC DISEASE; INFERIOR CAVA VEIN; LUNG ARTERY PRESSURE; MALE; OBSERVATIONAL STUDY; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION;

EID: 84907293796     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Fishman AP. Primary pulmonary arterial hypertension: a look back. J Am Coll Cardiol 2004;43:2S-4S.
2. Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease, part II, pathophysiology, clinical importance, and management of right ventricular failure. Circulation 2008;117:1717-31.
3. Galiè N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial analyses. Eur Heart J 2010;31:2080-6.
4. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Eng J Med 2004;351:1425-36.
5. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537.
6. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 Expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-619.
7. Forfia PR, Vachiéry JL. Echocardiography in pulmonary arterial hypertension. Am J Cardiol 2012;110:16S-24S.
8. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography. J Am Soc Echocardiogr 2010;23:685-713.
9. Hsu CH, Glassner C, Hsu HH, Maitland MG. Current therapeutics for pulmonary arterial hypertension. Acta Cardiol Sin 2012;28:267-78.
10. Galié N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:374-403.
11. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984;70:657-62.
12. Chemla D, Castelain V, Humbert M, et al. New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. Chest 2004;126:1313-7.
13. Steckelberg RC, Tseng AS, Nishimura R, et al. Derivation of mean pulmonary artery pressure from noninvasive parameters. J Am Soc Echocardiogr 2013;26:464-8.
14. Miyatake K, Yamagishi M, Tanak N, et al. New method for evaluating left ventricular wall motion by color-coded tissue Doppler imaging: in vitro and in vivo studies. J Am Coll Cardiol 1995;25:717-24.
15. Meluzin J, Spinarova L, Bakala J, et al. Pulsed Doppler tissue imaging of the velocity of tricuspid annular systolic motion: a new, rapid, and non-invasive method of evaluating right ventricular systolic function. Eur Heart J 2001;22:340-8.
16. Tei C, Dujardin KS, Hodge DO, et al. Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr 1996;9:838-47.
17. Abbas AE, Fortuin FD, Schiller NB, et al. A simple method for noninvasive estimation of pulmonary vascular resistance. J Am Coll Cardiol 2003;41:1021-7.
18. Opotowsky AR, Clair M, Afilalo J, et al. A simple echocardiographic method to estimate pulmonary vascular resistance. Am J Cardiol 2013;112:873-82.
19. Ryan T, Petrovic O, Dillon JC, et al. An echocardiographic index for separation right ventricular volume and pressure overload. J Am Coll Cardiol 1985;5:918-24.
20. Eysmann SB, Palevsky HI, Reichek N, et al. Two-dimensional and Doppler echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation 1989;80:353-60.
21. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-63.
22. McLaughlin VV, Badesch DB, Delcroix M, et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S97-107.
23. Benza RL, Gomberg-Maitland M, Miller DP, et al. The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary artery hypertension. Chest 2012;141:354-62.
24. Vlahos AP, Feinstein JA, Schiller NB, Silverman NH. Extension of Doppler-derived echocardiographic measures of pulmonary vascular resistance to patients with moderate or severe pulmonary vascular disease. J Am Soc Echocardiogr 2008;21:711-4.
25. Sitbon O, Baloira Villar AB, Bauer F, et al. Treat-to-target approach in pulmonary arterial hypertension: a consensus-based proposal. Eur Respir Rev 2012;21:259-62.
26. Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002;39:1214-9.
27. Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012;39:589-96.
28. Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary hypertension? : A meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012:60:1192-201.
29. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl JMed 2002;346:896-903.
30. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Eng J Med 2002;347:161-7.
31. Ho WJ, Hsu TS, Tsay PK, et al. Serial plasma brain natriuretic peptide testing in clinical management of pulmonary arterial hypertension. Acta Cardiol Sin 2009;25:147-53.
32. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865-70.